Corline Biomedical AB (CLBIO) — Cash Flow-to-Debt Ratio
Corline Biomedical AB (CLBIO) has a Cash Flow-to-Debt Ratio of -1.40x as of December 2025, meaning its operating cash flow of Skr-6.76 Million could theoretically repay -1% of its total liabilities (Skr4.82 Million) in one year. See free cash flow generation of Corline Biomedical AB to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Corline Biomedical AB Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Corline Biomedical AB across 13 annual periods. Also explore Corline Biomedical AB equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Corline Biomedical AB (2013–2025)
Year-by-year debt coverage analysis for Corline Biomedical AB. For market capitalisation and broader financial context, see Corline Biomedical AB stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.67x | Skr-17.69 Million | Skr4.82 Million | ▼ -233.5% |
| 2024 | -1.10x | Skr-8.64 Million | Skr7.85 Million | ▼ -943.5% |
| 2023 | 0.13x | Skr886.00K | Skr6.79 Million | ▲ +114.6% |
| 2022 | -0.90x | Skr-6.45 Million | Skr7.19 Million | ▼ -74.9% |
| 2021 | -0.51x | Skr-4.83 Million | Skr9.43 Million | ▲ +36.7% |
| 2020 | -0.81x | Skr-5.07 Million | Skr6.25 Million | ▲ +74.0% |
| 2019 | -3.12x | Skr-13.84 Million | Skr4.43 Million | ▼ -505.0% |
| 2018 | -0.52x | Skr-4.10 Million | Skr7.95 Million | ▲ +43.0% |
| 2017 | -0.90x | Skr-4.98 Million | Skr5.50 Million | ▲ +68.3% |
| 2016 | -2.85x | Skr-7.21 Million | Skr2.53 Million | ▼ -152.3% |
| 2015 | -1.13x | Skr-4.23 Million | Skr3.74 Million | ▼ -450.0% |
| 2014 | -0.21x | Skr-2.32 Million | Skr11.29 Million | ▲ +57.1% |
| 2013 | -0.48x | Skr-2.76 Million | Skr5.76 Million | — |